Radisys Celebrates Six Engage Digital Platform Winners of TADHack 2022 Hackathon
8.11.2022 22:30:00 EET | Business Wire | Press release
Radisys® Corporation, a global leader of open telecom solutions, is pleased to highlight the winners of the Engage Digital Platform real-world solutions in the 2022 TADHack Global, a hackathon focused on programmable communication solutions. Radisys provided participants in the Telecom Application Development (TAD) with access to its award-winning, no-code or low-code Engage Digital Platform to develop software projects or “hacks” that address customer challenges or use cases. Radisys’ Engage Digital Platform provides developers with a complete toolkit to create a full range of communication services, from voice and video calling, speech analytics and robust conversational AI-enabled digital engagement solutions.
The TADHack Global hackathon took place October 15-16, 2022, with participants competing across several cities and online. Radisys selected six winners, including a tie for third place and two specialized categories, for the best hacks from among the 23 submissions using Radisys’ Engage Digital Platform.
“I want to congratulate all of the 2022 TADHack Global event winners, especially those teams that leveraged Radisys’ Engage Digital Platform to develop such innovative solutions,” said Al Balasco, Head of Media, Core and Applications Business, Radisys. “The development of these amazing real-world solutions over a weekend was impressive and underscores the speed at which new ideas and applications can be developed and implemented. Hackathons like TADHack are a great way to showcase how MSPs and system integrators can benefit from an innovative developer ecosystem that is equipped with APIs and SDKs to create powerful advanced media applications they can integrate and offer as new services.”
Engage Digital Platform TADHack Global Winners
- First Place – Field Workforce Helper provides information from the inventory to support field workforce tasks, and routes Guard calls to the guard operator using an agenda in a Google spreadsheet, finally logging the call information in the spreadsheet. Team Member: Nacho Garmilla.
- Second Place – Secret Babble makes multilingual conversations more accessible by providing translations over the phone which can be read out loud by the system or sent discreetly as a text message, providing a transcription of the exchange. Team: Similarly Geeky; Team Members: Steve Goodwin & Lily Madar.
- Third Place – Blink is an application for crowded places designed to reduce the crowd and give people easy access to information about that particular place. It is used in places like hospitals, banks, shops, and airports, etc. Team: Sibane IT Solutions; Team Member: Linda Mosemaka.
- Third Place – Live Connect lets users connect to experts around the world for things such as learning a new language or finding a math or music tutor, to getting golf swing help and anything in between. Live Connect helps users find a suitable expert, book an appointment and connect via computer or phone using Radisys video APIs to bring the expert into customers’ homes. Team: Live Connect; Team Member: John Cakesy.
- Best Industry 4.0 Hack – FiremeX is a fire detection and alerting system that integrates computer vision, alert notifications and real-time audio calling when an event is detected. Team: RegeX; Team members: Nandula Perera, Raveen Fernando, Suvin Kodituwakku, Dilan Perera, Thenuka Ovin Weerasinghe.
- Disruptive Digital Engagement Hack – LifeVerse is a real-time health engagement platform that enables different types of clinics to be created and managed in the metaverse for both appointments and real-time consultations with patients. Team: LifeVerse; Team Members: Fahad Mahmood, Sarmad Faheem, Faheem Azhar.
To view videos of the six Engage Digital Platform winners and see all of the TADHack 2022 hacks visit https://www.engagedigital.ai/tadhack22.
About Radisys
Radisys, a global leader in open telecom solutions, enables service providers to drive disruption with new open architecture business models. Radisys’ innovative disaggregated and virtualized enabling technology solutions leverage open reference architectures and standards, combined with open software and hardware to power business transformation for the telecom industry, while its world-class services organization delivers systems integration expertise necessary to solve communications and content providers’ complex deployment challenges. For more information, visit www.radisys.com.
Radisys Engage Digital Platform was named both a 2022 Unified Communications Product of the Year Award winner and a Communications Product of the Year Award winner by TMC, a global, integrated media company covering multiple markets within the communications and technology industries, and won the Innovation in Digital Experience award in the 2022 Pipeline Innovation Awards, which recognizes the leading innovators transforming the industry with the most significant technological advancements. Engage Digital Platform was also named a “Highly Commended Best Comms Software” by the 2022 Comms Council UK Awards, a celebration of innovation in the telecom industry, and was selected as a finalist in the Best CPaaS Platform Award category by UC Today, a leading online publication for unified communications (UC) and collaboration technology. For more information, visit www.engagedigital.ai.
Radisys® is a registered trademark of Radisys. All other trademarks are the property of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221108006102/en/
Contact information
Nereus for Radisys
Matt Baxter, +1-503-619-0505
radisys@nereus-worldwide.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
